Europe Lung Cancer Therapeutics Market, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Country (U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe) Industry Trends and Forecast to 2028.
Market Analysis and Insights : Europe Lung Cancer Therapeutics Market
Data Bridge Market Research analyses that the Europe lung cancer therapeutics market to be growing at CAGR of 6.9% in the forecast period of 2021-2028 and is expected to reach the USD 2.85 billion by 2028.
Lung cancer is a type of cancer that reduces the efficiency of the lungs to deliver oxygen to the blood. It is one of the most common forms of cancer with the highest mortality rate. Lung cancer can be classified as an uncontrolled growth of cells in the lungs. Cigarette smoking, asbestos exposure, and smoking cigars are the main causes of lung cancer. This condition is characterized by weight loss, shortness of breath, cough and chest pain. Lung cancer is also called lung carcinoma.
The rise in the incidences of lung cancer and growing demand for targeted therapies along with the presence of highly-efficient drugs are the major factors that will influence the growth of lung cancer therapeutics market. Furthermore, environmental pollution, smoking, reimbursements, and rise in the health insurances are the drivers that will enhance the market's growth rate. Also, surge in the adoption rate of early detection and rising geriatric population will cushion the growth rate of lung cancer therapeutics market.
Moreover, increase in the research and development activities, introduction of nanomedicines for the treatment of lung cancer and rising approvals in lung cancer therapeutics will create beneficial opportunities for the market growth.
However, presence of generic drugs and high cost of the treatment coupled with the side effects associated with radiation and chemotherapies act as market restraints that will obstruct the market growth. Poor cancer diagnostic facilities and the lack of skilled professionals will further challenge the lung cancer therapeutics market.
This Europe lung cancer therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Europe lung cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Europe Lung Cancer Therapeutics Market Scope and Market Size
The Europe lung cancer therapeutics market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of cancer type, the lung cancer therapeutics market is segmented into non-small cell lung cancer, metastatic lung cancer, pulmonary neuroendocrine tumors, mediastinal tumors, mesothelioma and chest wall tumors.
- On the basis of molecule type, the lung cancer therapeutics market is segmented into small molecules and biologics.
- On the basis of drug class, the lung cancer therapeutics market is segmented into alkylating agents, antimetabolites, EGFR inhibitors, mitotic inhibitors, multikinase inhibitors and others.
- On the basis of treatment type, the lung cancer therapeutics market is segmented into chemotherapy, radiation therapy, targeted therapy, immunotherapy and others. Chemotherapy has been further sub-segmented into alimta, hycamtin, navelbine, taxotere and gemzar. Targeted therapy has been further sub-segmented into avastin, tarceva and iressa.
- On the basis of therapy type, the lung cancer therapeutics market is segmented into single drug therapy and combination therapy.
- On the basis of end user, the lung cancer therapeutics market is bifurcated into hospitals, homecare, speciality clinics and others.
- On the basis of distribution channel, the lung cancer therapeutics market is bifurcated into hospital pharmacy, retail pharmacy, online and others.
Europe Lung Cancer Therapeutics Market Country Level Analysis
The Europe lung cancer therapeutics market is analysed and market size insights and trends are provided by country, cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel as referenced above.
The countries covered in Europe lung cancer therapeutics market report are Germany, France, the U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and Rest of Europe.
U.K. dominates the Europe lung cancer therapeutics market due to the rise in the number of patients suffering from lung cancer in this region. Germany is expected to grow during the forecast period of 2021-2028 due to the increasing government funding for research and development of novel drugs and technological advancement.
The country section of the Europe lung cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Europe lung cancer therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Europe lung cancer therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Europe lung cancer therapeutics market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Europe Lung Cancer Therapeutics Market Share Analysis
The Europe lung cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Europe lung cancer therapeutics market.
The major players covered in the Europe lung cancer therapeutics market report are Takeda Pharmaceutical Company Limited., F. Hoffmann-La Roche Ltd., Novartis AG, Eli Lilly and Company, AstraZeneca, ONO PHARMACEUTICAL CO., LTD., Sanofi, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Johnson & Johnson Private Limited, Boehringer Ingelheim International GmbH., Allergan, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sumitomo Dainippon Pharma Co., Ltd., Amgen Inc., Astellas Pharma Inc., among other. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-